Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Teslas redesigned Roadster reveal, featuring SpaceX-developed thrusters and dramatic demonstrations, is driving discussion. Traders are split between praising the engineering spectacle and doubting its practicality, safety, road legality, and eventual production, while some speculate about deeper TeslaSpaceX ties.

IRENs sharp selloff is being discussed alongside broader weakness in AI data-center and neocloud stocks, as concerns about CoreWeaves borrowing costs have raised questions about sector financing and capital needs. Traders disagree on whether IREN is unfairly caught in the downturn given its comparatively stronger balance sheet, with some buying the dip and others warning that the decline may continue.

ServiceNows AI Passport launch with NVIDIA and upgrades to EmployeeWorks are drawing attention as signs of a push to make enterprise AI agents easier to deploy while keeping them governed. Traders are upbeat about the AI opportunity and the stocks momentum, though some point to resistance near recent highs and warn the gains may fade.

Zeta Lives AI product launches, including AthenaOS and an inference model built with NVIDIA technology, along with Palantir-related partnerships and subsequent analyst upgrades, are driving bullish attention. Traders point to Zetas enterprise AI opportunity, while skeptics warn the rally may be stretched and debate profit-taking ahead of earnings.

Omeros is drawing attention after Cantor Fitzgerald upgraded the stock, citing stronger-than-expected YARTEMLEA launch momentum and greater potential sales, following the drugs strong Q2 commercial uptake. Traders are broadly bullish on U.S. demand and upcoming Medicare reimbursement support, while some remain cautious about the upheld European rejection and whether sales can keep accelerating.

Netflixs appointment of former Disney and Fox executive Peter Rice as chief content officer is prompting debate over whether the leadership change can improve its content slate: some traders welcome a potential reset, while others doubt it will address concerns about programming and growth. The discussion is also shaped by the approaching earnings report and recent workforce cuts.

Repeated posts about GM-related litigation and recalls are drawing attention, particularly allegations of brake-cylinder failures in 2025 models and 6.2L V8 engine failures, alongside reminders that claims in the older fuel-pump settlement are closed. The discussion is cautionary, but the brake and engine issues remain allegations or matters under review, not newly certified class claims.

FMCs sharp third-quarter outlook cut, tied to weak demand, distributor inventory pressure, generic competition and planned price reductions, is driving attention. Traders largely fear further financial strain and question management, while some see an oversold buying opportunity or potential short squeeze.

Renewed interest in rare-earth stocks and concern about reliance on Chinese supply are drawing attention to ALOY, with traders highlighting its U.S. Army-linked processing plans and Tanbreez offtake agreement as potential beneficiaries of domestic supply-chain efforts. The community is divided between investors betting on those strategic prospects and skeptics focused on the stocks declines, limited company updates and execution risks.

QCis collaboration with INmune Bio to use its Dirac-3S system for Alzheimers trial-data analysis is drawing attention, with bullish traders calling it an early commercial validation of the technology. The optimism is tempered by skepticism about whether the product will deliver and by debate over a possible short squeeze after the stocks prolonged decline.